Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
How It Works 
News - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI Summary - About
Pulse Biosciences Inc(PLSE)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Stock price based on last close Advisory Performance History (Simulated)
Upturn Advisory & Investor View for PLSE
09/25/2026: PLSE (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Pulse Biosciences is a clinical-stage medical device company specializing in Nanosecond Pulsed Field Ablation (nsPFA) technology. Its primary strength lies in this proprietary platform, which has shown promise in treating both dermatological conditions and, more recently, cardiac arrhythmias. The primary growth story centers on successfully penetrating the vast cardiac surgery market, which offers significant long-term potential. However, the company faces substantial risks, including fierce competition from well-established industry giants, the need for continued regulatory success, and high execution hurdles. This stock is best suited for growth-oriented investors with high risk tolerance who are closely monitoring clinical trial milestones and commercial adoption progress.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Mixed fit | The company offers high-risk, high-reward exposure to an emerging medical technology platform. |
| Momentum investor | Strong fit while signal remains positive | The stock can exhibit high momentum during periods of positive clinical data or regulatory progress. |
| Value investor | Weak fit | The company is not currently profitable, making traditional valuation metrics inapplicable. |
| Dividend investor | Weak fit | There is no dividend history or expectation of payouts in the near future. |
| Low-risk investor | Weak fit | Significant business, regulatory, and financial risks make this unsuitable for low-risk portfolios. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | High | Speculative nature and low market capitalization lead to frequent and sharp price swings. |
| Valuation risk | High | Difficult to value without sustained revenue or profitability. |
| Competition risk (Medical Technology) | High | Directly competes against well-entrenched industry leaders with greater resources. |
| Business quality | Medium | The technology is promising, but the business is still in a nascent development stage. |
| Dividend income | Low / none | No income potential exists for investors. |
| Execution risk | High | Success depends heavily on complex regulatory approvals and clinical trial results. |
Price Behavior
Hockey-Stick Growth
The stock demonstrates a Hockey-Stick Growth price path pattern.
Extreme Price Shocks
The stock has experienced exceptionally large and disruptive price movements during the period.
Analysis of Past Performance
Type Stock | Historic Profit -3.83% | Avg. Invested days 25 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Advisory Rating  | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/25/2026 |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals
Financial Health Rating
Growth Momentum Score
Ownership
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue)
Economic Dimensions
Quantitative Style Profile
Style Classification
Quality Focused
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 3.68B USD | Price to earnings Ratio - | 1Y Target Price 54 |
Price to earnings Ratio - | 1Y Target Price 54 | ||
Volume (30-day avg) 603.5K shares | Beta 1.62 | 52 Weeks Range 12.56 - 58.90 | Updated Date 09/27/2026 |
52 Weeks Range 12.56 - 58.90 | Updated Date 09/27/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.17 |
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| CellFX System Sales | Sale of the CellFX console and single-use delivery devices for dermatological procedures. | Revenue is earned from selling medical equipment and the associated consumable tips required for each procedure. |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Valuation
Trailing PE - | Forward PE - | Enterprise Value 3.61B | Price to Sales(TTM) 3107.5 |
Enterprise Value 3.61B | Price to Sales(TTM) 3107.5 | ||
Enterprise Value to Revenue 3043.71 | Enterprise Value to EBITDA -1.81 | Shares Outstanding 71.32M | Shares Floating 20.65M |
Shares Outstanding 71.32M | Shares Floating 20.65M | ||
Percent Insiders 71.05 | Percent Institutions 15.43 |
Upturn AI Summary
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.
About Pulse Biosciences Inc
Exchange NASDAQ | Headquarters Miami, FL, United States | ||
IPO Launch date 2016-05-18 | President, CEO & Co-Chairman of the Board Mr. Paul Arthur LaViolette M.B.A. | ||
Sector Healthcare | Industry Medical Instruments & Supplies | Full time employees 116 | Website https://www.pulsebiosciences.com |
Full time employees 116 | Website https://www.pulsebiosciences.com | ||
Pulse Biosciences, Inc. operates as a novel bioelectric medicine company. It offers nPulse System, a novel Nanosecond Pulsed-Field Ablation delivery platform to treat benign lesions of the skin; nPulse Vybrance Percutaneous Electrode system for soft tissue ablation in surgical setting; nPulse Cardiac Surgical Clamp designed for use in surgical treatment of atrial fibrillation (AF); nPulse Cardiac Catheter System designed to provide a circumferential, or circular, ablation in a single treatment cycle; and nPulse Console, a software-enabled console-based platform designed to accommodate the clinical workflow preferred by physicians. The company was formerly known as Electroblate, Inc. and changed its name to Pulse Biosciences, Inc. in December 2015. Pulse Biosciences, Inc. was incorporated in 2014 and is headquartered in Miami, Florida.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.